Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ARBUTUS BIOPHARMA CORP reported revenue of $14M, up 128.2% year over year. Operating margin was -271.0% and net margin -237.9%, on a free-cash-flow margin of -281.5% with capital expenditure at 0.0% of revenue. Every figure is computed directly from ABUS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $14M | -271.0% | -237.9% |
| FY2024 | $6M | -1236.7% | -1133.0% |
| FY2023 | $18M | -430.5% | -401.6% |
| FY2022 | $39M | -167.8% | -178.0% |
| FY2021 | $11M | -669.1% | -693.9% |
How does ABUS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: PG · JNJ · ABBV · BMY · ABT · AMGN
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.